Results 121 to 130 of about 44,597 (222)

Concurrent Bladder Urothelial Carcinoma and Prostate Tuberculosis: A Case Report. [PDF]

IJU Case Rep
Suzuki R, Kawai T.
europepmc   +1 more source

Sarcomatoid urothelial carcinoma of the bladder

Asian Journal of Surgery
Cungeng Fan, Binglin Lai
openaire   +3 more sources

Reducing complexity in International Bladder Cancer Group intermediate‐risk non‐muscle‐invasive bladder cancer stratification: a three‐factor approach

BJU International, Volume 138, Issue 2, Page 244-249, August 2026.
Objectives To evaluate whether a simplified risk model preserves the prognostic performance of the International Bladder Cancer Group (IBCG) five‐factor risk stratification model in intermediate‐risk (IR) non‐muscle‐invasive bladder cancer (NMIBC). Patients and Methods We performed a multicentre retrospective analysis of 2822 patients with IR NMIBC ...
Jayant Siva, Can Aydogdu, Nicholas Heller, Rishi Jonnalagadda, Patrick J. Hensley, Gabriela M. Diaz, Sean McSweeney, Rebecca Campbell, Nima Almassi, Reza Alaghehbandan, Christopher J. Weight, Ashish M. Kamat, Laura Bukavina   +12 more
wiley   +1 more source

Bioinformatics analysis and clinical validation identify <i>FBXW9</i> as a biomarker in bladder urothelial carcinoma. [PDF]

Transl Androl Urol
Li D, Wu W, Chen Y, Liang Z, Zhang Q, Yuan C, Liao S, Liao Y, Si W, Yu X, Huang M.   +10 more
europepmc   +1 more source

FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate

Histopathology, Volume 89, Issue 2, Page 240-250, August 2026.
FOXA1 is a highly sensitive diagnostic marker for prostate cancer. Besides prostatic adenocarcinoma, it is also expressed in 57%–80% of metastatic or primary prostatic small cell carcinomas, which lose traditional prostatic markers including NKX3.1. Although it is less specific than NKX3.1, it can serve as a valuable adjunct for confirming prostatic ...
Jianping Zhao, Jun Yao, Hossein Hosseini, Ezra Baraban, Ruihe Lin, Charles C. Guo, Lei Huo, Wei Lu, Khaja Khan, Shufang Wang, Luisa Maren Solis Soto, Qingqing Ding   +11 more
wiley   +1 more source

Marked attenuation of P63 expression in plasmacytoid urothelial carcinoma with expanded immunohistochemical framework including E‐cadherin, P120, HER2 and TRPS1

Histopathology, Volume 89, Issue 2, Page 338-346, August 2026.
Plasmacytoid urothelial carcinoma demonstrates marked attenuation of p63 expression together with frequent disruption of the E‐cadherin–p120 adhesion complex, supporting its characteristic discohesive growth pattern. Standardized HER2 scoring identifies a substantial positive subset, highlighting diagnostic pitfalls and potential therapeutic relevance ...
Busra Yaprak Bayrak, Kemal Kosemehmetoglu, Busra Ozbek, Sercan Simsek, Murat Oktay, Ganime Coban, Dilara Irem Arslan Kahraman, Egemen Akıncıoglu, Melek Buyukgok, Selin Colak, Hatice Nese Dogan, Burak Gurel, Selva Kabul, Kerem Karaca, Elif Ozsagir, Ece Ozturk, Havva Serap Toru, Gupse Turan, Nazif Alperen Yıldırım, Ozlem Nur Yıldız, Yasemin Yuyucu Karabulut, Liang Cheng, Mahmut Akgul   +22 more
wiley   +1 more source

Integrated Ferroptosis and Immune Features Are Associated With Overall Survival in Bladder Urothelial Carcinoma: A TCGA-Based Analysis. [PDF]

Cancer Inform
Zhang L, Sheng Z.
europepmc   +1 more source

The Role of Natural Compounds in Bladder Urothelial Carcinoma Treatment. [PDF]

Int J Mol Sci
Jiang H, Chen Y, Zeng X, Yang R, Zhang F, Zhang H, Zhang E, Wu X, Yan D, Yu C.   +9 more
europepmc   +1 more source

Bladder melanosis with concurrent urothelial carcinoma

Urology Case Reports, 2017
Susanna E. Yau, Eric J. Singer, Yue Sun, Michael H. Johnson   +3 more
openaire   +3 more sources

Characterization of Immune Infiltrating Cells in Bladder Urothelial Carcinoma and Its Clinical Significance. [PDF]

Cancer Med
Yan X, Tang X, Guo L, He Z, Liu S, Wu S, Li Z, Liu TZ, Zheng H, Zhang W, Li S.   +10 more
europepmc   +1 more source